Skip to main content
. 2022 Jun 16;139(24):3546–3557. doi: 10.1182/blood.2021014520

Table 1.

Cohort characteristics

Patients
Characteristic n %
Full cohort, n 295 100
Recipient age, median (range) 66 (6-76)
Recipient sex
 Female 117 40
 Male 178 60
HCT-CI score
 0 83 28
 1-2 81 27
 3+ 120 40
 Missing 11 4
Type of AML (clinically defined)
De novo 173 59
 Secondary 91 31
 Therapy-related 31 11
Cytogenetics *
 Normal 136 46
 Core binding factor 6 2
 Complex karyotype 41 14
 Other 112 38
2017 ELN risk group
 Favorable 53 18
 Intermediate 85 29
 Adverse 152 52
 Missing 5 2
Initial therapy
 Intensive induction 249 84
 Non-intensive induction 46 16
Reinduction
 Yes 90 31
 No 204 69
 Missing 1 0.3
Remission quality
 CR with hematologic recovery 225 75
 CRi 67 23
 Missing 1 0.3
Donor type
 Matched related 54 18
 Matched unrelated 154 52
 Mismatch related 7 2
 Mismatch unrelated 29 10
 Haploidentical 51 17
Conditioning regimen
 Myeloablative 28 9
 Reduced intensity 267 91
  T-cell depletion 25 9
Stem cell source
 Peripheral blood 216 73
 Bone marrow 71 24
 Umbilical cord blood 8 3

Shown are the pretransplant characteristics of the 295 patients included in the cohort. HCT-CI: hematopoietic cell transplant comorbidity index score. CRi denotes complete remission with incomplete recovery of at least 1 hematopoietic cell lineage.

ELN, European Leukemia Network.

*

Core binding factor: inv(16) or t(8;21); complex karyotype: 3 or more chromosomal abnormalities within a single clone.